Cardiol Therapeutics Capital Expenditures (CapEx) Growth & History (CRDL)
Cardiol Therapeutics's capital expenditures (capex) was $24,484 for fiscal 2025.
View full Cardiol Therapeutics company overviewCardiol Therapeutics annual capital expenditures (capex) history
| Fiscal year | Period ended | Capital expenditures (CapEx) | Change | Growth |
|---|---|---|---|---|
| 2025 | 2025-12-31 | $24,484 | $3,194 | +15.00% |
| 2024 | 2024-12-31 | $21,290 | −$43,022 | −66.90% |
| 2023 | 2023-12-31 | $64,312 | −$10,397 | −13.92% |
| 2022 | 2022-12-31 | $74,709 | $61,793 | +478.42% |
| 2021 | 2021-12-31 | $12,916 | −$27,686 | −68.19% |
| 2020 | 2020-12-31 | $40,602 | — | — |
Cardiol Therapeutics quarterly capital expenditures (capex)
| Fiscal quarter | Period ended | Capital expenditures (CapEx) | Change | YoY change |
|---|---|---|---|---|
| Q2 2026 | 2026-06-30 | $3,029 | −$3,410 | −52.96% |
| Q1 2026 | 2026-03-31 | $47,585 | $35,646 | +298.57% |
| Q4 2025 | 2025-12-31 | $3,088 | — | — |
| Q3 2025 | 2025-09-30 | $3,018 | — | — |
| Q2 2025 | 2025-06-30 | $6,439 | — | — |
| Q1 2025 | 2025-03-31 | $11,939 | — | — |
Cardiol Therapeutics capital expenditures (capex) trends
Over the last five fiscal years, Cardiol Therapeutics's capital expenditures (capex) decreased from $40,602 to $24,484, a change of −$16,118. The latest reported quarter, Q2 2026, shows $3,029.
What capital expenditures (CapEx) mean
Capital expenditures, commonly called CapEx, are cash investments in long-lived assets such as property, plants, equipment, infrastructure, and productive software. CapEx can support future growth or maintain existing operations, but it reduces current-period free cash flow.
SEC-reported capital expenditures
TickerStat standardizes cash payments for property, plant, equipment, and other productive assets reported in company SEC filings. When a filer reports separate qualifying CapEx components instead of a total, those components are combined for the same fiscal period. Fiscal periods can differ from calendar years, so exact period-end dates are included.
Review Cardiol Therapeutics source filings ↗